The use of a paclitaxel eluting balloon in small vessels

Original title: A Randomized Multicenter Study Comparing a Paclitaxel Drug-Eluting Balloon With a Paclitaxel-Eluting Stent in Small Coronary Vessels. The BELLO (Balloon Elution and Late Loss Optimization) Study Reference: Referencia: Azeem Latib et al J Am Coll Cardiol 2012;()doi:10.1016/j.jacc.2012.09.020

The utility of paclitaxel-eluting balloons to treat in-stent restenosis is known but data for novo lesions is more limited. 

The aim of this study was to evaluate the efficacy of paclitaxel-eluting balloons (PEB) compared with paclitaxel-eluting stents (PES) for the reduction of restenosis in small vessels. This multicenter and prospective study randomized 182 patients with lesions in small vessels (reference diameter <2.8 mm) to receive a paclitaxel eluting balloon and provisional conventional stent (n = 90) or a paclitaxel-eluting stent. 

The primary endpoint of non-inferiority was late lumen loss with a delta of 0.25 mm. Secondary end points were binary restenosis, TLR and MACE, (death, myocardial infarction and revascularization), at 6 months. Both groups were well balanced except for the smallest diameter in PEB-treated vessels, (2.15 ± 0.27 mm vs. 2.25 ± 0.24 mm, p = 0.003). 20% of the PEB group required a conventional stent rescue after dilation. 

The primary end point was significantly lower with PEB compared with PES, (0.08 ± 0.38 mm vs. 0.29 ± 0.44 mm, p for noninferiority <0.001, p for superiority = 0.001). At 6 months both were similar in binary restenosis, (PEB 8.9% versus PES 14.1%, P = 0.25), TLR, (PEB 4.4% versus PES 7.6%, p = 0.37), and MACE, (PEB 7.8% versus DES 13.2%, P = 0.77).

Conclusion 

Small-vessel angioplasty using PEB had a lower late lumen loss with similar restenosis and revascularization than paclitaxel-eluting stents at 6 months.

Editorial Comment:

The results are promising, especially considering that the average size of the vessels was <2.5 mm. It would be very interesting to track this in a longer-term study and with a primary clinical purpose as well as a comparison against edge limus eluting stents.

SOLACI.ORG

More articles by this author

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...

Comparison of strategies: NMA of IVUS, OCT, or angiography in complex lesions

Percutaneous coronary intervention (PCI) in complex lesions continues to represent a technical challenge in contemporary interventional cardiology. Angiography, although it remains the most widely...

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...